Three-Year Safety and Efficacy of Benralizumab for Adolescent Patients with Severe, Uncontrolled Asthma: Results of the BORA Extension Study

      Adults and adolescents with severe asthma who completed the SIROCCO (48 weeks) and CALIMA (56 weeks) Phase III benralizumab trials entered the safety extension BORA (NCT02258542) study. Benralizumab’s continued safety and efficacy in the first year of BORA (Year 2 of treatment) have been reported (Lancet Respir Med 2019;7:46–59). We present outcomes for 2 years of benralizumab treatment for BORA adolescent patients.
      To read this article in full you will need to make a payment


      Subscribe to Journal of Allergy and Clinical Immunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect